{"analyses":[{"ciNumSides":"TWO_SIDED","groupDescription":"Assess Baseline Tumor SUV Mean Association With LRPF using Hazard ratios along with the associated p-values to compare arms","groupIds":["OG001","OG002"],"nonInferiorityType":"SUPERIORITY","pValue":"0.7997","paramType":"Hazard Ratio (HR)","paramValue":"1.225","statisticalMethod":"Regression, Cox"},{"ciNumSides":"TWO_SIDED","groupDescription":"Assess Baseline Tumor SUV Max Association With LRPF using Hazard ratios along with the associated p-values to compare arms","groupIds":["OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.8704","paramType":"Hazard Ratio (HR)","paramValue":"1.049","statisticalMethod":"Regression, Cox"},{"ciNumSides":"TWO_SIDED","groupDescription":"Assess Baseline Tumor SUV Peak Association With LRPF using Hazard ratios along with the associated p-values to compare arms","groupIds":["OG001","OG002"],"nonInferiorityType":"SUPERIORITY","pValue":"0.7699","paramType":"Hazard Ratio (HR)","paramValue":"1.106","statisticalMethod":"Regression, Cox"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.33","value":"1.60"},{"groupId":"OG001","spread":"0.17","value":"1.48"},{"groupId":"OG002","spread":"0.39","value":"1.68"}]}],"title":"TUMOR SUV(MEAN)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.81","value":"2.73"},{"groupId":"OG001","spread":"0.55","value":"2.50"},{"groupId":"OG002","spread":"1.03","value":"2.88"}]}],"title":"TUMOR SUV(MAX) All"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.71","value":"2.23"},{"groupId":"OG001","spread":"0.46","value":"2.05"},{"groupId":"OG002","spread":"0.82","value":"2.34"}]}],"title":"TUMOR SUV(PEAK)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"23"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"14"}],"units":"Participants"}],"description":"Baseline PET-MISO measures are normalized to blood uptake (ie., tumor-to-blood pool ratio) : Tumor SUV Mean, Tumor SUV Max, Tumor SUV Peak Association with LRPF 2-years post registration (That is, evaluate baseline FMISO-PET uptake as a prognostic marker of LRPF)","dispersionType":"Standard Deviation","groups":[{"description":"Patients undergo chemoradiotherapy as defined for the arm of the study to which they were randomized.\n\n18F-Fluoromisonidazole: Undergo FMISO PET/CT prior to therapy for patients enrolling at institutions participating in the FMISO correlative study","id":"OG000","title":"Both Arms"},{"description":"Patients undergo standard radiotherapy QD 5 days a week for 30 fractions. Patients also receive paclitaxel IV over 1 hour and carboplatin IV over 30 minutes once weekly for 6 weeks. Patients undergo FMISO-PET imaging at baseline\n\n18F-Fluoromisonidazole: Undergo FMISO PET/CT prior to therapy for patients enrolling at institutions participating in the FMISO correlative study\n\nCarboplatin: Given IV\n\nExternal Beam Radiation Therapy: Undergo radiotherapy","id":"OG001","title":"Arm I (Standard Chemoradiotherapy)"},{"description":"Patients undergo an individualized dose of image-guided radiotherapy QD 5 days a week for 30 fractions and undergo 18 F FDG-PET/CT between fractions 18 and 19. Based on the scan results, patients undergo individualized adaptive radiotherapy for the final 9 fractions. Patients also receive paclitaxel and carboplatin as in Arm I.\n\n18F-Fluoromisonidazole: Participants enrolled at institutions participating in the FMISO correlative study undergo FMISO-PET prior to treatment\n\nCarboplatin: Given IV\n\nComputed Tomography: Undergo FDG PET/CT\n\nComputed Tomography: Undergo FMISO PET/CT (Correlative studies)\n\nFludeoxyglucose F-18: Undergo FDG PET/CT\n\nImage-Guided Adaptive Radiation Therapy: Undergo individualized adaptive radiotherapy\n\nLaboratory Biomarker Analysis: Correlative studies\n\nPaclitaxel: Given IV\n\nPositron Emission Tomography: Undergo FDG PET/CT\n\nPositron Emission Tomography: Undergo FMISO PET/CT (Correlative studies)","id":"OG002","title":"Arm II (Experimental Chemoradiotherapy)"}],"paramType":"MEAN","populationDescription":"Participants enrolled at an institution participating in the FMISO Correlative Study. Note that the company supplying FMISO ceased production early in the study.","reportingStatus":"POSTED","timeFrame":"Baseline and 2-years after randomization","title":"Baseline 18F-fluoromisonidazole (FMISO) Uptake (Tumor-to-blood Pool Ratio) Measures Association With LRPF 2-years Post Registration (ECOG-ACRIN)","type":"SECONDARY","unitOfMeasure":"SUV"}